About Genesis Therapeutics
Genesis Therapeutics is a private company based in Burlingame, California, incorporated in 2019 in Delaware. It has reported $297,437,884 raised in three offerings on Form D since December 2020. Its chief executive is Evan Feinberg.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2023 | Aug 25, 2023 | $224,025,681fully sold | 50 | $4.4M | EquityRule 506(b) | Form D ↗ |
| Jun 22, 2022 | Dec 23, 2022 | $23,894,572fully sold | 33 | $724K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 24, 2020 | Dec 9, 2020 | $49,517,631target not set | 24 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $297,437,884 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Genesis Therapeutics's Form D filed Aug 25, 2023.
VP
Vijay Pande
Director
EF
Evan Feinberg
PRESIDENT and CEO, director
PP
Peptiboon Prasit
Executive officer and director
WM
William Mccarthy
Executive officer
LB
Leonard Bell
Director
KJ
Kris Jenner
Director
BS
Benjamin Sklaroff
Executive officer
Earlier filings also listed Stephen Dann (executive officer, last listed Dec 2022) and Nicholas Stock (executive officer, last listed Dec 2020).